These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 21802122)

  • 21. Angiotensin-converting enzyme insertion/deletion and angiotensin type 1 receptor A1166C polymorphisms as genetic risk factors in benign prostatic hyperplasia and prostate cancer.
    Sierra Díaz E; Sánchez Corona J; Rosales Gómez RC; Gutierrez Rubio SA; Vázquez Camacho JG; Solano Moreno H; Morán Moguel MC
    J Renin Angiotensin Aldosterone Syst; 2009 Dec; 10(4):241-6. PubMed ID: 20026870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men.
    Marchesani M; Hakkarainen A; Tuomainen TP; Kaikkonen J; Pukkala E; Uimari P; Seppälä E; Matikainen M; Kallioniemi OP; Schleutker J; Lehtimäki T; Salonen JT
    J Natl Cancer Inst; 2003 Jun; 95(11):812-8. PubMed ID: 12783936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA hypermethylation and epigenetic silencing of the tumor suppressor gene, SLC5A8, in acute myeloid leukemia with the MLL partial tandem duplication.
    Whitman SP; Hackanson B; Liyanarachchi S; Liu S; Rush LJ; Maharry K; Margeson D; Davuluri R; Wen J; Witte T; Yu L; Liu C; Bloomfield CD; Marcucci G; Plass C; Caligiuri MA
    Blood; 2008 Sep; 112(5):2013-6. PubMed ID: 18566324
    [TBL] [Abstract][Full Text] [Related]  

  • 24. P53 codon 72 (Arg72Pro) polymorphism and prostate cancer risk: association between disease onset and proline genotype.
    Rogler A; Rogenhofer M; Borchardt A; Lunz JC; Knoell A; Hofstaedter F; Tannapfel A; Wieland W; Hartmann A; Stoehr R
    Pathobiology; 2011; 78(4):193-200. PubMed ID: 21778786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.
    Gu C; Li Q; Zhu Y; Qu Y; Zhang G; Wang M; Yang Y; Wang J; Jin L; Wei Q; Ye D
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):310-6. PubMed ID: 26238235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sodium-coupled monocarboxylate transporter is a target of epigenetic repression in cervical cancer.
    Hernández-Juárez J; Vargas-Sierra O; Herrera LA; Cantú De León D; Fernández-Retana J; Pérez-Plasencia C; López-Camarillo C; Gariglio P; Díaz-Chávez J
    Int J Oncol; 2019 May; 54(5):1613-1624. PubMed ID: 30896789
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SLC5A8 (SMCT1)-mediated transport of butyrate forms the basis for the tumor suppressive function of the transporter.
    Gupta N; Martin PM; Prasad PD; Ganapathy V
    Life Sci; 2006 Apr; 78(21):2419-25. PubMed ID: 16375929
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PSCA rs1045531 Polymorphism and the Risk of Prostate Cancer in a Chinese Population Undergoing Prostate Biopsy.
    Zhang X; Hu Q; Chen Y; Li M; Yin H; Zhou C; Li G; Hou J
    Technol Cancer Res Treat; 2017 Dec; 16(6):1168-1172. PubMed ID: 29332451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort.
    Sun T; Mary LG; Oh WK; Freedman ML; Pomerantz M; Pienta KJ; Kantoff PW
    Clin Cancer Res; 2011 Mar; 17(6):1546-52. PubMed ID: 21135144
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An NKX3.1 binding site polymorphism in the l-plastin promoter leads to differential gene expression in human prostate cancer.
    Chen C; Cai Q; He W; Li Z; Zhou F; Liu Z; Zhong G; Chen X; Zhao Y; Dong W; Huang J; Zheng J; Lin T
    Int J Cancer; 2016 Jan; 138(1):74-86. PubMed ID: 26148677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic variation in nucleotide excision repair pathway genes, pesticide exposure and prostate cancer risk.
    Barry KH; Koutros S; Andreotti G; Sandler DP; Burdette LA; Yeager M; Beane Freeman LE; Lubin JH; Ma X; Zheng T; Alavanja MC; Berndt SI
    Carcinogenesis; 2012 Feb; 33(2):331-7. PubMed ID: 22102698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Functional identification of SLC5A8, a tumor suppressor down-regulated in colon cancer, as a Na(+)-coupled transporter for short-chain fatty acids.
    Miyauchi S; Gopal E; Fei YJ; Ganapathy V
    J Biol Chem; 2004 Apr; 279(14):13293-6. PubMed ID: 14966140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression of slc5a8 in kidney and its role in Na(+)-coupled transport of lactate.
    Gopal E; Fei YJ; Sugawara M; Miyauchi S; Zhuang L; Martin P; Smith SB; Prasad PD; Ganapathy V
    J Biol Chem; 2004 Oct; 279(43):44522-32. PubMed ID: 15322102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer.
    Tanaka Y; Sasaki M; Shiina H; Tokizane T; Deguchi M; Hirata H; Hinoda Y; Okayama N; Suehiro Y; Urakami S; Kawakami T; Kaneuchi M; Pookot D; Igawa M; Okuyama A; Ishii N; Dahiya R
    Cancer Epidemiol Biomarkers Prev; 2006 Feb; 15(2):238-44. PubMed ID: 16492910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk.
    Sun J; Wiklund F; Hsu FC; Bälter K; Zheng SL; Johansson JE; Chang B; Liu W; Li T; Turner AR; Li L; Li G; Adami HO; Isaacs WB; Xu J; Grönberg H
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):480-5. PubMed ID: 16537705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SLC5A8 triggers tumor cell apoptosis through pyruvate-dependent inhibition of histone deacetylases.
    Thangaraju M; Gopal E; Martin PM; Ananth S; Smith SB; Prasad PD; Sterneck E; Ganapathy V
    Cancer Res; 2006 Dec; 66(24):11560-4. PubMed ID: 17178845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-nucleotide polymorphisms in DNMT3B gene and DNMT3B mRNA expression in association with prostate cancer mortality.
    Zelic R; Fiano V; Ebot EM; Coseo Markt S; Grasso C; Trevisan M; De Marco L; Delsedime L; Zugna D; Mucci LA; Richiardi L
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):284-291. PubMed ID: 30341411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen and 17-hydroxylase polymorphic genotypes in patients with prostate cancer and benign prostatic hyperplasia.
    Gunes S; Bagci H; Sarikaya S; Bilen CY; Kara N
    DNA Cell Biol; 2007 Dec; 26(12):873-8. PubMed ID: 17961073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TRPV6 alleles do not influence prostate cancer progression.
    Kessler T; Wissenbach U; Grobholz R; Flockerzi V
    BMC Cancer; 2009 Oct; 9():380. PubMed ID: 19857260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.